Athenex ATNX Stock
Athenex Price Chart
Athenex ATNX Financial and Trading Overview
Athenex stock price | 1.34 USD |
Previous Close | 0.2 USD |
Open | 0.22 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 900 |
Day's Range | 0.2 - 0.2 USD |
52 Week Range | 0.08 - 23.8 USD |
Volume | 1.75M USD |
Avg. Volume | 263.31K USD |
Market Cap | 2.33M USD |
Beta (5Y Monthly) | 1.345179 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.5 USD |
ATNX Valuation Measures
Enterprise Value | 82.22M USD |
Trailing P/E | N/A |
Forward P/E | -0.13361841 |
PEG Ratio (5 yr expected) | 0 |
Price/Sales (ttm) | 0.02269653 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 0.8 |
Enterprise Value/EBITDA | -1.145 |
Trading Information
Athenex Stock Price History
Beta (5Y Monthly) | 1.345179 |
52-Week Change | -98.97% |
S&P500 52-Week Change | 20.43% |
52 Week High | 23.8 USD |
52 Week Low | 0.08 USD |
50-Day Moving Average | 0.95 USD |
200-Day Moving Average | 3.35 USD |
ATNX Share Statistics
Avg. Volume (3 month) | 263.31K USD |
Avg. Daily Volume (10-Days) | 477.36K USD |
Shares Outstanding | 8.7M |
Float | 6.5M |
Short Ratio | 5.24 |
% Held by Insiders | 9.73% |
% Held by Institutions | 29.87% |
Shares Short | 356.33K |
Short % of Float | 5.17% |
Short % of Shares Outstanding | 4.11% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -100.58% |
Operating Margin (ttm) | -72.10% |
Gross Margin | 25.96% |
EBITDA Margin | -69.84% |
Management Effectiveness
Return on Assets (ttm) | -19.65% |
Return on Equity (ttm) | -1927.27% |
Income Statement
Revenue (ttm) | 102.82M USD |
Revenue Per Share (ttm) | 15.72 USD |
Quarterly Revenue Growth (yoy) | 110.90% |
Gross Profit (ttm) | 26.7M USD |
EBITDA | -71813000 USD |
Net Income Avi to Common (ttm) | -97979000 USD |
Diluted EPS (ttm) | -10.45 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 31.51M USD |
Total Cash Per Share (mrq) | 3.64 USD |
Total Debt (mrq) | 129.1M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.087 |
Book Value Per Share (mrq) | -0.754 |
Cash Flow Statement
Operating Cash Flow (ttm) | -75014000 USD |
Levered Free Cash Flow (ttm) | -28800250 USD |
Profile of Athenex
Country | United States |
State | NY |
City | Buffalo |
Address | Conventus Building |
ZIP | 14203 |
Phone | 716 427 2950 |
Website | https://www.athenex.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 269 |
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Q&A For Athenex Stock
What is a current ATNX stock price?
Athenex ATNX stock price today per share is 1.34 USD.
How to purchase Athenex stock?
You can buy ATNX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Athenex?
The stock symbol or ticker of Athenex is ATNX.
Which industry does the Athenex company belong to?
The Athenex industry is Drug Manufacturers-Specialty & Generic.
How many shares does Athenex have in circulation?
The max supply of Athenex shares is 8.78M.
What is Athenex Price to Earnings Ratio (PE Ratio)?
Athenex PE Ratio is 0.00000000 now.
What was Athenex earnings per share over the trailing 12 months (TTM)?
Athenex EPS is 0 USD over the trailing 12 months.
Which sector does the Athenex company belong to?
The Athenex sector is Healthcare.
Athenex ATNX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}